Table 1.
Characteristics of the study patients (n = 543).
| Characteristics | Value |
|---|---|
| No. of patients | 543 |
| Sex Male Female |
191(35.2%) 352(64.8%) |
| Age at diagnosis (y), median (range) <55 ≥55 |
39(6-76) 481(88.6%) 62(11.4%) |
| Extent of lymph node dissection Central lymph node dissection Lateral lymph node dissection Central and lateral lymph node dissection |
247(45.5%) 19(3.5%) 277(51.0%) |
| Histology Classic PTC FV-PTC FTC Aggressive histology |
519(95.6%) 9(1.7%) 5(0.9%) 10(1.8%) |
| Incomplete tumor resection | 8(1.5%) |
| Gross ETE | 87(16.0%) |
| BMI(kg/m2) <18.5 18.5-24 >24 |
52(9.8%) 287(52.9%) 190(35.0%) |
| Primary tumor size (cm), median (range) | 1.5cm(0–9cm) |
| Bilateral tumor | 177(32.6%) |
| Multifocal tumor | 253(46.6%) |
| Capsular invasion | 325(59.9%) |
| Invasion of loco-regional tissues or structures | 133(24.5%) |
| Vascular invasion | 64(11.8%) |
| Invade nerves | 41(7.6%) |
| Ta T0 T1 T2 T3 T4 Tx |
3(0.6%) 329(62.3%) 93(17.6%) 67(12.7%) 34(6.4%) 2(0.4%) |
| Na N0 N1a N1b |
48(8.8%) 252(46.4%) 243(44.8%) |
| Initial risk stratification Low risk Intermediate risk High risk |
64(11.8%) 405(74.6%) 74(13.6%) |
| BRAFV600E mutation of primary tumor | 366(80.8%) |
| Number of invaded lymph nodes, median (range) >5 ≤5 |
5(0-79) 220(40.1%) 323(58.9%) |
| Size of the largest metastatic LN(cm),median (range) | 0.4cm(0–5cm) |
| Extranodal extension of LN | 199(46.1%) |
| Multiple RAI ablation | 101(18.6%) |
| Cumulative 131I-administered activities(GBq), median (range) <7.40 ≥7.40 |
5.55(1.85-22.94) 440(81.0%) 103(19.0%) |
| Ps-Tg (ng/mL), median (range) <10 ≥10 |
4.47(0.04-1511.20) 360(66.3%) 183(33.7%) |
| TSH(μIU/mL), median (range) <30 ≥30 |
63.19(5.26-115.92) 22(4.1%) 521(95.9%) |
| TGAb (kU/L), median (range) | 14.31(10.00-114.60) |
| Follow-up information Median follow-up (m), median (range) | 63 (24-122) |
| Last status No evidence of disease Persistent structural disease Persistent biomedical disease Recurrent structural disease Recurrent biomedical disease |
414(76.2%) 68(12.5%) 16(2.9%) 38(7.1%) 7(1.3%) |
PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; FV-PTC, follicular variant PTC; ps-Tg, pre-ablation stimulated thyroglobulin; LN, lymph node; BMI, Body Mass Index; ETE, extrathyroidal extension. TSH, thyroid stimulating hormone; TGAb, thyroglobulin antibody. aTNM staging was determined by 8th American Joint Cancer Committee Tumor-Node-Metastasis stage system.